1.Botulinum Toxin Type A Injection for Management of Upper Limb Spasticity in Children with Cerebral Palsy: a Literature Review.
Yonsei Medical Journal 2006;47(5):589-603
The aim of this article was to present a review of the research literature on the outcome of botulinum toxin type A (BTX-A) injection for management of upper limb spasticity in children with cerebral palsy (CP). We searched the electronic databases of MEDLINE, CINAHL and PUBMED for all published studies with full-length English text available. For each study, the quality of the methods and the strength of evidence were assessed by 2 independent reviewers based on the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) guidelines. Four studies of level I, 8 studies of level IV and 4 studies of level V were identified. Due to the limited number of studies with high quality evidence and inconsistent results among studies, we were unable to support or refute the usefulness of BTX-A injection for management of upper limb spasticity in children with CP. Moreover, we identified several variables that may affect the outcome of injection, such as timing of age, dosage, dilution volumes, localization techniques of target muscles and participant characteristics. In summary, we have presented a review the literature and a discussion of the considerable uncertainty and variation associated with the clinical use of BTX-A injection for management of upper limb spasticity in children with CP.
Upper Extremity
;
Range of Motion, Articular/drug effects
;
Neuromuscular Agents/administration & dosage/*therapeutic use
;
Muscle Spasticity/drug therapy
;
Injections
;
Infant
;
Humans
;
Child, Preschool
;
Child
;
Cerebral Palsy/*drug therapy
;
Botulinum Toxin Type A/administration & dosage/*therapeutic use
;
Age Factors
;
Adult
;
Adolescent
2.Double-Blind, Randomized, Comparative Study of Meditoxin(R) Versus Botox(R) in the Treatment of Essential Blepharospasm.
Jin Sook YOON ; Jae Chan KIM ; Sang Yeul LEE
Korean Journal of Ophthalmology 2009;23(3):137-141
PURPOSE: To compare the efficacies and safeties of Meditoxin(R) (Medy-Tox, Korea) and Botox(R) in the treatment of essential blepharospasm. METHODS: We performed a double-blind, randomized, comparative trial comparing Meditoxin(R) and Botox(R) for treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after injection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety evaluation. RESULTS: Improvement in SS was noted in 90.3% of the Meditoxin(R) group and 86.2% of the Botox(R) group. There were no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since the lower limit of the 95% confidence interval (-1.76% for ITT, -1.64% for PP) was over the -15% threshold, we determined that Meditoxin(R) was not inferior to Botox(R) in either the ITT or PP populations. Adverse effects developed in 16.1% of the Meditoxin(R) group and 27.6% of the Botox(R) group, but no serious adverse events were found in either group. CONCLUSIONS: Meditoxin(R) and Botox(R) were comparable in efficacy and safety in the treatment of essential blepharospasm.
Aged
;
Blepharospasm/*drug therapy/physiopathology
;
Botulinum Toxin Type A/*administration & dosage/adverse effects
;
Double-Blind Method
;
Female
;
Humans
;
Injections
;
Male
;
Middle Aged
;
Neuromuscular Agents/*administration & dosage/adverse effects
;
Treatment Outcome
3.The Changes in Corneal Astigmatism after Botulinum Toxin-A Injection in Patients with Blepharospasm.
Nam Ju MOON ; Hyeon Il LEE ; Jae Chan KIM
Journal of Korean Medical Science 2006;21(1):131-135
To determine if the involuntary contractions of eyelids may have any effects on the development of corneal astigmatism, we performed this prospective study which includes 19 patients with either essential blepharospasm or hemifacial spasm. In hemifacial spasm, the degree of corneal astigmatism was evaluated between two eyes. Then the topographic changes were checked using vector analysis technique before and after passively opening the eyelids. They were also measured before and at 1 and 6 months after the injection of Botulinum toxin. Resultantly, 20 eyes had the with-the-rule (group1) and 9 eyes against-the-rule (group2) astigmatism. In hemifacial spasm, significantly more astigmatism was found at spastic eyes. The corneal topographic changes after passively opening the eyelids showed 10 eyes with the astigmatic shift to the with-the-rule, while the remaining 19 to the againstthe- rule. At 1 month after injection of Botulinum toxin, group 1 showed reduced average corneal astigmatism, whereas group 2 showed increased astigmatism. The astigmatic change vector showed significantly more against-the-rule. In the contrary, 6 months after treatment, corneal astigmatism again increased in group 1 and decreased in group 2. So they took on the appearance of pretreatment astigmatic status eventually. Conclusively eyelids may play an important role in corneal curvature.
Aged
;
Astigmatism/*drug therapy/physiopathology
;
Blepharospasm/*drug therapy/physiopathology
;
Botulinum Toxin Type A/administration & dosage/*therapeutic use
;
Cornea/drug effects/physiopathology
;
Corneal Diseases/*drug therapy/physiopathology
;
Eyelids/drug effects/physiopathology
;
Female
;
Humans
;
Injections
;
Male
;
Middle Aged
;
Time Factors
;
Treatment Outcome